| 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,8 M € | — | — | — | — | — | — | — | — | — | ||||||||||
| Gross margin | 254,1 k € | -76.9% | 1,1 M € | +0.7% | 1,1 M € | -14.5% | 1,3 M € | +345.1% | -521,4 k € | -1526.4% | -32,1 k € | +82.1% | -179,6 k € | -476.9% | 47,6 k € | +134.6% | -137,7 k € | -476.1% | -23,9 k € | |
| EBITDA | -3,9 M € | -7.4% | -3,6 M € | +20.3% | -4,6 M € | -45.7% | -3,1 M € | -87.0% | -1,7 M € | -246.0% | -483,6 k € | -30.4% | -370,9 k € | -2946.9% | 13,0 k € | +108.0% | -163,1 k € | -411.2% | -31,9 k € | |
| Operating profit | -8,3 M € | -7.1% | -7,8 M € | -5.3% | -7,4 M € | -43.5% | -5,1 M € | -125.1% | -2,3 M € | -170.5% | -842,6 k € | +5.0% | -887,1 k € | -574.5% | -131,5 k € | +28.9% | -185,1 k € | -264.8% | -50,7 k € | |
| Profit/loss | -6,9 M € | -15.0% | -6,0 M € | +4.4% | -6,3 M € | -34.7% | -4,7 M € | -164.2% | -1,8 M € | -152.3% | -703,0 k € | -33.7% | -525,7 k € | -147.5% | -212,4 k € | -14.9% | -184,9 k € | -264.5% | -50,7 k € | |
| Equity | 22,8 M € | -17.2% | 27,5 M € | +68.9% | 16,3 M € | -19.5% | 20,2 M € | +653.3% | 2,7 M € | +74.5% | 1,5 M € | -17.3% | 1,9 M € | +240.4% | 547,3 k € | +1636.6% | -35,6 k € | -123.9% | 149,3 k € | |
| Total assets | 42,3 M € | +11.8% | 37,9 M € | +39.7% | 27,1 M € | -17.2% | 32,7 M € | +346.4% | 7,3 M € | +117.9% | 3,4 M € | +24.1% | 2,7 M € | +115.7% | 1,3 M € | +200.2% | 418,8 k € | +99.4% | 210,1 k € | |
| Cash | 1,2 M € | +17.5% | 1,0 M € | -70.2% | 3,5 M € | -74.3% | 13,5 M € | +2242.1% | 576,5 k € | +18.5% | 486,5 k € | -71.5% | 1,7 M € | +778.1% | 194,3 k € | -8.8% | 212,9 k € | +38.0% | 154,2 k € | |
| Debts | 19,5 M € | +89.2% | 10,3 M € | -4.1% | 10,8 M € | -13.5% | 12,5 M € | +168.1% | 4,6 M € | +154.5% | 1,8 M € | +115.0% | 849,2 k € | +19.6% | 709,9 k € | +56.2% | 454,5 k € | +647.6% | 60,8 k € | |
| Staff | 33,5 | 34 | 40 | 32 | — | — | — | 0,7 | 0,5 | 0,1 | ||||||||||
Public limited company · Seraing · incorporated on 20/12/2012 · 33,5 ETP
Public limited company loss-making in the latest fiscal year. Cash position rising (+17.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
EYED PHARMA is a Public limited company incorporated in 2012. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Seraing. It employs on average 33,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette